Modulation of Phospho-CREB by Systemically Administered Recombinant BDNF in the Hippocampus of the R6/2 Mouse Model of Huntington’s Disease

Figure 5

Expression level of pCREB and BDNF in the hippocampus DG, CA1, and CA3 regions of R6/2 injected with BDNF. Mice hippocampus was removed and the DG, CA1, and CA3 regions were isolated and lysate to perform western blot assay. Panels (a) and (b) show the decrease of pCREB expression levels, especially in the CA3 region and a statistically significant increment in BDNF treated R6/2, p<0,001. (c) Bonferroni posttest for repeated-measures comparison showed a significant increment of BDNF protein levels in treated-R6/2 DG and CA1 regions compared to vehicle treated mice, p<0,001.

(a)

(b)

(c)